Sutro Biopharma, Inc. (STRO) Misses Q3 EPS by 27c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.67), $0.27 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $9.69 million versus the consensus estimate of $10.1 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Trump: not sure I want to make a deal with Iranian leaders
• Trump: don't think war with Iran will start again, will make things safer for oil
• Trump: I think Israel will withdraw troops from Lebanon